^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carfilzomib

    i
    Other names: PR-171, ONO 7057, ONO-7057, ONO7057, PR171, PR 171
    Company:
    Generic mfg.
    Drug class:
    Proteasome inhibitor
    Related drugs:
    2d
    COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    clonoSEQ
    |
    Darzalex (daratumumab) • carfilzomib • dexamethasone • iberdomide (CC-220)
    3d
    ATLAS: Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, University of Chicago | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    lenalidomide • carfilzomib • dexamethasone
    3d
    Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib (clinicaltrials.gov)
    P=N/A, N=50, Terminated, University of Chicago | Trial completion date: Aug 2026 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Sep 2025; Study terminated by PI
    Trial completion date • Trial termination • Trial primary completion date
    |
    carfilzomib
    10d
    M22-574: A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monotherapy Study) (2023-506668-15-00)
    P2/3, N=147, Active, not recruiting, AbbVie Deutschland GmbH & Co. KG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • etentamig intravenous (ABBV-383 IV)
    14d
    ADAPT: Carfilzomib and Belatacept for Desensitization (clinicaltrials.gov)
    P1/2, N=21, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | N=15 --> 21 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    carfilzomib
    18d
    M25-059: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in combination with Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib (2024-515770-27-00)
    P1/2, N=10, Not yet recruiting, AbbVie Deutschland GmbH & Co. KG
    New P1/2 trial • Adverse events
    |
    lenalidomide • carfilzomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    18d
    R5458-ONC-2246: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy with Standard-of-Care Combination Regimens in Adult Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (2024-519504-27-00)
    P2/3, N=315, Not yet recruiting, Regeneron Pharmaceuticals Inc.
    New P2/3 trial
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • Lynozyfic (linvoseltamab-gcpt)
    18d
    Anti-myeloma activity of the CXCR4 antagonist WZ811. (PubMed, J Mol Med (Berl))
    Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.  KEY MESSAGES: WZ811 reduced the viability of myeloma primary cells and cell lines. WZ811 eliminated the MM stem cell-like side population. WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12)
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • carfilzomib • pomalidomide
    21d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2028 | Initiation date: Jan 2026 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Chr del(17p)
    |
    clonoSEQ
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    22d
    Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma. (PubMed, Cancers (Basel))
    Background/Objectives: Carfilzomib (CFZ) and bortezomib (BTZ) are proteasome inhibitors used as the first-line therapy for relapsed or refractory multiple myeloma (MM) but are associated with cardiovascular adverse events (CVAEs). Pathway enrichment analyses identified peroxisome, MAPK, Rap1, adherens junction, phospholipase D, autophagy, and aldosterone-related pathways to be implicated in CVAEs. Our study identified distinct DMPs, DMRs, and pathways enrichment associated with CVAE, suggesting epigenetic contributors to CVAEs and supporting the need for larger validation studies.
    Journal
    |
    USP18 (Ubiquitin Specific Peptidase 18)
    |
    bortezomib • carfilzomib
    22d
    Dual Targeting of IDH2 and the Ubiquitin-Proteasome System Reveals a Functional Vulnerability in Breast Cancer Models. (PubMed, Cancers (Basel))
    A panel of human and murine breast cancer cell lines was treated with the IDH2 inhibitor AGI-6780, alone or in combination with the proteasome inhibitor carfilzomib (CFZ) or the E1 ubiquitin-activating enzyme inhibitor TAK-243. Inhibition of IDH2 markedly enhances the cytotoxic effects of proteasome-targeting by disrupting metabolic-proteostatic balance and promoting apoptotic cell death. These findings identify a growth-inhibitory effect that may be leveraged to improve functional dependency in breast cancer, particularly in triple-negative breast cancer, which currently lacks efficient drug treatments.
    Preclinical • Journal
    |
    IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CASP3 (Caspase 3)
    |
    carfilzomib • AGI-6780 • TAK-243
    24d
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • mezigdomide (CC-92480)